Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Current Oncology Reports
Erschienen in: Current Oncology Reports 4/2012

01.08.2012 | Sarcomas (SR Patel, Section Editor)

Current State-of-the-Art Systemic Therapy for Pediatric Soft Tissue Sarcomas

verfasst von: Anish Ray, Winston W. Huh

Erschienen in: Current Oncology Reports | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Pediatric soft tissue sarcomas (STS) are a heterogeneous group of tumors. Rhabdomyosarcomas (RMS) are the most common histologic subtype, while synovial sarcomas and undifferentiated sarcomas are among the more common non-rhabdomyosarcomatous soft tissue sarcomas (NRSTS) encountered. While the survival outcome for certain groups of RMS patients is quite good, the prognosis for those with alveolar histology or those with metastatic or relapsed disease remains dismal. Also, the response rate for some NRSTS to conventional chemotherapy is suboptimal. Thus increased understanding of involved molecular pathways, such as the insulin growth factor and mammalian target of rapamycin pathways, may indicate potential targets for therapy. In addition, immunotherapy-based approaches that include both non-specific activation with interleukins as well as targeted tumor antigen specific T lymphocytes are emerging avenues in the treatment of children with soft tissue sarcomas.
Literatur
1.
2.
Okcu MF, Hicks J, et al. The nonrhabdomyosarcoma soft tissue sarcomas. In: Pizzo PA, editor. Principles and Practice of Pediatric Oncology. 6th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2010. p. 954–86.
3.
Ferrari A, Sultan I, Huang TT, Rodriguez-Galindo C, Shehadeh A, Meazza C, et al. Soft tissue sarcoma across the age spectrum: a population-based study from the Surveillance Epidemiology and End Results database. Pediatr Blood Cancer. 2011;57:943–9.PubMedCrossRef
4.
Marcus KC, Grien HE, Shamberger RC, Gebhardt MC, PerezAtayde A, Silver B, et al. Childhood soft tissue sarcoma: A 20-year experience. J Pediatr. 1997;131:603–7.PubMedCrossRef
5.
Ognjanovic S, Linabery AM, Charbonneau B, Ross JA. Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975–2005. Cancer. 2009;115:4218–26.PubMedCrossRef
6.
Li FP, Fraumeni J. F. Rhabdomyosarcoma in children—epidemiologic study and identification of a familial cancer syndrome. J Natl Cancer Inst. 1969;43:1365–73.PubMed
7.
Samuel DP, Tsokos M, DeBaun MR. Hemihypertrophy and a poorly differentiated embryonal rhabdomyosarcoma of the pelvis. Med Pediatr Oncol. 1999;32:38–43.PubMedCrossRef
8.
Jones AE, Albano EA, Lovell MA, Hunger SP. Metastatic alveolar rhabdomyosarcoma in multiple endocrine neoplasia type 2A. Pediatr Blood Cancer. 2010;55:1213–6.PubMedCrossRef
9.
Crist W, Gehan EA, Ragab AH, Dickman PS, Donaldson SS, Fryer C, et al. The third intergroup rhabdomyosarcoma study. J Clin Oncol. 1995;13:610–30.PubMed
10.
•• Sorensen PHB, Lynch JC, Qualman SJ, Tirabosco R, Lim JF, Maurer HM, et al. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: A report from the children’s oncology group. J Clin Oncol. 2002;20:2672–9. This report from a COG study addresses the genetic basis underlying the poor outcome seen in alveolar rhabdomyosarcoma. PubMedCrossRef
11.
Williamson D, Missiaglia E, de Reynies A, Pierron G, Thuille B, Palenzuela G, et al. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. J Clin Oncol. 2010;28:2151–8.PubMedCrossRef
12.
Neerav Shukla NA, Yilmaz I, Nafa K, Lau C-Y, Marchetti A, Borsu L, Barr FG, Ladanyi M. Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways. Clin Cancer Res. 2012;18:748–57.PubMedCrossRef
13.
Chen Y, Takita J, Mizuguchi M, Tanaka K, Ida K, Koh K, et al. Mutation and expression analyses of the MET and CDKN2A genes in rhabdomyosarcoma with emphasis on MET overexpression. Genes Chromosomes Cancer. 2007;46:348–58.PubMedCrossRef
14.
Mercado GE, Xia SJ, Zhang C, Ahn EH, Gustafson DM, Lae M, et al. Identification of PAX3-FKHR-regulated genes differentially expressed between alveolar and embryonal rhabdomyosarcoma: Focus on MYCN as a biologically relevant target. Genes Chromosomes Cancer. 2008;47:510–20.PubMedCrossRef
15.
Oberlin O, Rey A, Lyden E, Bisogno G, Stevens MCG, Meyer WH, et al. Prognostic factors in metastatic rhabdomyosarcomas: Results of a pooled analysis from United States and European cooperative groups. J Clin Oncol. 2008;26:2384–9.PubMedCrossRef
16.
Sultan I, Casanova M, Al-Jumaily U, Meazza C, Rodriguez-Galindo C, Ferrari A. Soft tissue sarcomas in the first year of life. Eur J Canc. 2010;46:2449–56.
17.
Breneman JC, Lyden E, Pappo AS, Link MP, Anderson JR, Parham DM, et al. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma—A report from the intergroup rhabdomyosarcoma study IV. J Clin Oncol. 2003;21:78–84.PubMedCrossRef
18.
Arndt CAS, Stoner JA, Hawkins DS, Rodeberg DA, Hayes-Jordan AA, Paidas CN, et al. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children’s oncology group study D9803. J Clin Oncol. 2009;27:5182–8.PubMedCrossRef
19.
Crist WM, Anderson JR, Meza JL, Fryer C, Raney RB, Ruymann FB, et al. Intergroup rhabdomyosarcoma study-IV: Results for patients with nonmetastatic disease. J Clin Oncol. 2001;19:3091–102.PubMed
20.
Dantonello TM, Int-Veen C, Harms D, Leuschner I, Schmidt BF, Herbst M, et al. Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults. J Clin Oncol. 2009;27:1446–55.PubMedCrossRef
21.
McDowell HP, Foot ABM, Ellershaw C, Machin D, Giraud C, Bergeron C. Outcomes in paediatric metastatic rhabdomyosarcoma: results of The International Society of Paediatric Oncology (SIOP) study MMT-98. Eur J Cancer. 2010;46(9):1588–95.PubMedCrossRef
22.
Dantonello TM, Winkler P, Boelling T, Friedel G, Schmid I, Mattke AC, et al. Embryonal rhabdomyosarcoma with metastases confined to the lungs: report from the CWS Study Group. Pediatr Blood Cancer. 2011;56(5):725–32.PubMedCrossRef
23.
Klingebiel T, Boos J, Beske F, Hallmen E, int-Veen C, Dantonello T, et al. Treatment of children with metastatic soft tissue sarcoma with oral maintenance compared to high dose chemotherapy: report of the HD CWS-96 trial. Pediatr Blood Cancer. 2008;50:739–45.PubMedCrossRef
24.
Admiraal R, van der Paardt M, Kobes J, Kremer LCM, Bisogno G, Merks JHM. High-dose chemotherapy for children and young adults with stage IV rhabdomyosarcoma. Cochrane Database Syst Rev. 2010;12:CD006669.
25.
Chisholm J, Marandet J, Rey A, Oberlin O. Prognostic factors after relapse in non-metastatic rhabdomyosarcoma: who can be salvaged? Pediatr Blood Cancer. 2010;55:836.
26.
Pappo AS, Anderson JR, Crist WM, Wharam MD, Breitfeld PP, Hawkins D, et al. Survival after relapse in children and adolescents with rhabdomyosarcoma: A report from the intergroup rhabdomyosarcoma study group. J Clin Oncol. 1999;17:3487–93.PubMed
27.
McNall-Knapp RY, Williams CN, Reeves EN, Heideman RL, Meyer WH. Extended phase I evaluation of vincristine, irinotecan, temozolomide, and antibiotic in children with refractory solid tumors. Pediatr Blood Cancer. 2010;54:909–15.PubMedCrossRef
28.
Wagner LM, Perentesis JP, Reid JM, Ames MM, Safgren SL, Nelson Jr MD, et al. Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children’s Oncology Group phase I consortium study. Pediatr Blood Cancer. 2010;54:538–45.PubMed
29.
Casanova M, Ferrari A, Bisogno G, Merks JHM, De Salvo GL, Meazza C, et al. Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas—Pilot study for the upcoming European rhabdomyosarcoma protocol. Cancer. 2004;101:1664–71.PubMedCrossRef
30.
Rapkin L QM, Brill P, Martin M, Clark D, George BA et al. Gemcitabine and docetaxel (GEMDOX) for the treatment of relapsed and refractory pediatric sarcomas. Pediatr Blood Cancer. 2012.
31.
Chang FJ, Syrjanen S, Syrjanen K. Implications of the p53 tumor-suppressor gene in clinical oncology. J Clin Oncol. 1995;13:1009–22.PubMed
32.
Khoury JD, Coffin CM, Spunt SL, Anderson JR, Meyer WH, Parham DM. Grading of nonrhabdomyosarcoma soft tissue sarcoma in children and adolescents: a comparison of parameters used for the Fédération Nationale des Centers de Lutte Contre le Cancer and Pediatric Oncology Group Systems. Cancer. 2010;116:2266–74.PubMed
33.
Hawkins DS, Schuetze SM, Butrynski JE, Rajendran JG, Vernon CB, Conrad EU, et al. [F-18] fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. J Clin Oncol. 2005;23:8828–34.PubMedCrossRef
34.
Brems H, Beert E, de Ravel T, Legius E. Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1. Lancet Oncol. 2009;10:508–15.PubMedCrossRef
35.
Evans DGR, Baser ME, Friedman JM, McGaughran J, Timms B, Moran A. Malignant peripheral nerve sheath tumors in neurofibromatosis 1. Am J Hum Genet. 2001;69:311–4.CrossRef
36.
Carli M, Ferrari A, Mattke A, Zanetti I, Casanova M, Bisogno G, et al. Pediatric malignant peripheral nerve sheath tumor: The Italian and German soft tissue sarcoma cooperative group. J Clin Oncol. 2005;23:8422–30.PubMedCrossRef
37.
•• Ferner RE, Gutmann DH. International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis 1. Cancer Res. 2002;62:1573–7. An excellent review by a panel of experts who have formulated a standardized approach in diagnosing and treating neurofibromatosis type 1 patients who develop malignant peripheral nerve sheath tumors. PubMed
38.
Yang J, Ylipaa A, Sun Y, Zheng H, Chen K, Nykter M, et al. Genomic and molecular characterization of malignant peripheral nerve sheath tumor identifies the IGF1R pathway as a primary target for treatment. Clin Cancer Res. 2011;17:7563–73.PubMedCrossRef
39.
Torres KE, Zhu Q-S, Bill K, Lopez G, Ghadimi MP, Xie X, et al. Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors. Clin Cancer Res. 2011;17:3943–55.PubMedCrossRef
40.
Palmerini E, Staals EL, Alberghini M, Zanella L, Ferrari C, Benassi MS, et al. Synovial sarcoma. Cancer. 2009;115:2988–98.PubMedCrossRef
41.
Okcu MF, Munsell M, Treuner J, Mattke A, Pappo A, Cain A, et al. Synovial sarcoma of childhood and adolescence: A multicenter, multivariate analysis of outcome. J Clin Oncol. 2003;21:1602–11.PubMedCrossRef
42.
Brennan B, Stevens M, Kelsey A, Stiller CA. Synovial sarcoma in childhood and adolescence: a retrospective series of 77 patients registered by the Children’s Cancer and Leukaemia Group between 1991 and 2006. Pediatr Blood Cancer. 2010;55:85–90.PubMed
43.
Pappo AS, Devidas M, Jenkins J, Rao B, Marcus R, Thomas P, et al. Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: A pediatric oncology group study. J Clin Oncol. 2005;23:4031–8.PubMedCrossRef
44.
Sultan I, Rodriguez-Galindo C, Saab R, Yasir S, Casanova M, Ferrari A. Comparing children and adults with synovial sarcoma in the Surveillance, Epidemiology, and End Results program, 1983 to 2005: an analysis of 1268 patients. Cancer. 2009;115:3537–47.PubMedCrossRef
45.
Teng H, Wang H, Chen W, Chao T, Hsieh Y, Hsih C, Tzeng C, Chen P, Yen C. Prevalence and prognostic influence of genomic changes of EGFR pathway markers in synovial sarcoma. J Surg Oncol. 2011;103:773–81.PubMedCrossRef
46.
Friedrichs N, Trautmann M, Endl E, Sievers E, Kindler D, Wurst P, et al. Phosphatidylinositol-3 ′-kinase/AKT signaling is essential in synovial sarcoma. Int J Cancer. 2011;129:1564–75.PubMedCrossRef
47.
Nakayama R, Mitani S, Nakagawa T, Hasegawa T, Kawai A, Morioka H, et al. Gene expression profiling of synovial sarcoma: distinct signature of poorly differentiated type. Am J Surg Pathol. 2010;34:1599–607.PubMed
48.
Alaggio R, Bisogno G, Rosato A, Ninfo V, Coffin CM. Undifferentiated sarcoma: does it exist? A clinicopathologic study of 7 pediatric cases and review of literature. Hum Pathol. 2009;40:1600–10.PubMedCrossRef
49.
Geoerger B, Kieran MW, Grupp S, Perek D, Clancy J, Krygowski M, et al. Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma. Eur J Cancer. 2012;48:253–62.PubMedCrossRef
50.
• Ganjoo K, Jacobs C. Antiangiogenesis agents in the treatment of soft tissue sarcomas. Cancer. 2010;116:1177–83. A good synopsis of the molecules upregulated in the angiogenesis pathways in soft tissue sarcomas. PubMedCrossRef
51.
Gerber HP, Kowalski J, Sherman D, Eberhard DA, Ferrara N. Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res. 2000;60:6253–8.PubMed
52.
Bender JLG, Adamson PC, Reid JM, Xu L, Baruchel S, Shaked Y, et al. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: A children’s oncology group study. J Clin Oncol. 2008;26:399–405.CrossRef
53.
Petrillo M, Scambia G, Ferrandina G. Novel targets for VEGF-independent anti-angiogenic drugs. Expert Opin Investig Drugs. 2012;21(4):451–72.
54.
Hilbert M, Mary P, Larroquet M, Serinet M-O, Helfre S, Brisse H, et al. Alveolar soft part sarcoma in childhood: Is Sunitinib-Sutent (R) treatment an effective approach? Pediatr Blood Cancer. 2011;58:475–6.PubMedCrossRef
55.
56.
57.
Fox E, Aplenc R, Bagatell R, Chuk MK, Dombi E, Goodspeed W, et al. A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors. J Clin Oncol. 2010;28:5174–81.PubMedCrossRef
58.
• Leroith D, Werner H, Beitnerjohnson D, Roberts CT. Molecular and cellular aspects of the insulin-like growth-factor-I receptor. Endocr Rev. 1995;16:143–63. This a good example that illustrate the role played by the IGF1 pathway in patients with sarcomas, and provide a basis for targeted therapy for treating such patients. PubMed
59.
• Pappo AS, Patel SR, Crowley J, Reinke DK, Kuenkele K-P, Chawla SP, et al. R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. J Clin Oncol. 2011;29:4541–7. This another good example that illustrate the role played by the IGF1 pathway in patients with sarcomas, and provide a basis for targeted therapy for treating such patients. PubMedCrossRef
60.
Malempati S, Weigel B, Ingle AM, Ahern CH, Carroll JM, Roberts CT, et al. Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children’s Oncology Group. J Clin Oncol. 2012;30:256–62.PubMedCrossRef
61.
Meadors JL, Cui Y, Chen Q-R, Song YK, Khan J, Merlino G, et al. Murine rhabdomyosarcoma is immunogenic and responsive to T-cell-based immunotherapy. Pediatr Blood Cancer. 2011;57:921–9.PubMedCrossRef
62.
•• Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2010;29:917–24. This immunotherapy based clinical trial demonstrates objective response using adoptive transfer of T cells among patients with synovial sarcoma and melanoma. The response duration is meaningful (>1 year) and will likely lead to other similar trials. CrossRef
63.
Mackall CL, Rhee EH, Read EJ, Khuu HM, Leitman SF, Bernstein D, et al. A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas. Clin Cancer Res. 2008;14:4850–8.PubMedCrossRef
64.
Robertson MJ, Ritz J. Biology and clinical relevance of human natural-killer-cells. Blood. 1990;76:2421–38.PubMed
65.
Cho D, Shook DR, Shimasaki N, Chang Y-H, Fujisaki H, Campana D. Cytotoxicity of activated natural killer cells against pediatric solid tumors. Clin Cancer Res. 2010;16:3901–9.PubMedCrossRef
66.
Denman CJ, Senyukov VV, Somanchi SS, Phatarpekar PV, Kopp LM, Johnson JL, et al. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PloS One. 2012;7(1):e30264.
67.
Meazza C, Casanova M, Zaffignani E, Luksch R, Podda M, Favini F, et al. Efficacy of topotecan plus vincristine and doxorubicin in children with recurrent/refractory rhabdomyosarcoma. Med Oncol. 2009;26:67–72.PubMedCrossRef
68.
Baruchel S, Pappo A, Krailo M, Baker KS, Wu B, Villaluna D, et al. A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: A report from the Children’s Oncology Group. Eur J Cancer. 2012;48:579–85.PubMedCrossRef
Metadaten
Titel
Current State-of-the-Art Systemic Therapy for Pediatric Soft Tissue Sarcomas
verfasst von
Anish Ray
Winston W. Huh
Publikationsdatum
01.08.2012
Verlag
Current Science Inc.
Erschienen in
Current Oncology Reports / Ausgabe 4/2012
Print ISSN: 1523-3790
Elektronische ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-012-0243-y

Weitere Artikel der Ausgabe 4/2012

Current Oncology Reports 4/2012 Zur Ausgabe

Lung Cancer (T Mekhail, Section Editor)

Current Developments in the Management of Locally Advanced Esophageal Cancer

Palliative Medicine (A Jatoi, Section Editor)

VEGF Inhibition, Hypertension, and Renal Toxicity

Palliative Medicine (A Jatoi, Section Editor)

Incidence and Management of Gastrointestinal Perforation from Bevacizumab in Advanced Cancers

Sarcomas (SR Patel, Section Editor)

Progress in Radiotherapy for Pediatric Sarcomas

Palliative Medicine (A Jatoi, Section Editor)

The Double Edged Sword of Bleeding and Clotting from VEGF Inhibition in Renal Cancer Patients

Sarcomas (SR Patel, Section Editor)

Advances in Adjuvant Therapy of Gastrointestinal Stromal Tumors

Neu im Fachgebiet Onkologie

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Blutdrucksenkung könnte Uterusmyome verhindern

21.05.2024 Krebsvorsorge in der Gynäkologie Nachrichten

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise